| A selective alpha-1 adrenoceptor antagonist, silodosin, is used for the treatment of benign prostatic hyperplasia. However,
because of silodosin's short half-life, the drug needs to be administered frequently, resulting in patients not adhering to the
treatment plan. During the present study, the aim was to formulate and evaluate controlled release matrix microspheres of
silodosin in order to improve the therapeutic efficacy of the drug and the compliance of the patient. We characterized the
particle size, the encapsulation efficiency, and the release of drugs from the prepared microspheres in vitro in order to
evaluate their efficacy. Upon analysis of the particle size distribution, it was found that the microspheres had an average
size range of m and were uniformly spherical. By scanning electron microscopy (SEM), we were able to observe that the
microspheres had a smooth surface morphology. The results of this study suggest that the controlled release matrix
microspheres of silodosin are effective in prolonging release time, reducing the frequency of dosing, and possibly
improving patient compliance by prolonging the release of the drug. Silodosin could be significantly enhanced in its
effectiveness if a controlled release formulation is developed, and this study provides a promising approach towards the
development of such a formulation.ddd |
